Associated Papers
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
SNAr Reactive Pyrazine Derivatives as p53-Y220C Cleft Binders with Diverse Binding Modes.
Klett T et al.
Drug Design, Development and Therapy, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer.
Yang H et al.
Cancer Cell, 2024
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.
Ben-Cohen G et al.
Briefings in Bioinformatics, 2022
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule.
Grinkevich VV et al.
Frontiers in Molecular Biosciences, 2022
FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.
Cui D et al.
Cell Reports, 2020
Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor.
Tripathi V et al.
The Journal of Biological Chemistry, 2019
Temporal and differential regulation of KAISO-controlled transcription by phosphorylated and acetylated p53 highlights a crucial regulatory role of apoptosis.
Choi SH et al.
The Journal of Biological Chemistry, 2019
Systematic analysis of the intersection of disease mutations with protein modifications.
Simpson CM et al.
Bmc Medical Genomics, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy.
Simon CM et al.
Cell Reports, 2017
Distribution bias analysis of germline and somatic single-nucleotide variations that impact protein functional site and neighboring amino acids.
Pan Y et al.
Scientific Reports, 2017
Mutation spectrum of hepatocellular carcinoma from eastern-European patients betrays the impact of a complex exposome.
Tanase AM et al.
Journal of Exposure Science & Environmental Epidemiology, 2015
DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair.
Serrano MA et al.
Oncogene, 2013
p53 Ser15 phosphorylation disrupts the p53-RPA70 complex and induces RPA70-mediated DNA repair in hypoxia.
Madan E et al.
The Biochemical Journal, 2012
Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.
Warnock LJ et al.
Cancer Biology & Therapy, 2011
p53-dependent apoptosis in response to spindle damage is linked to loss of Bub1.
Beeharry N et al.
Cancer Biology & Therapy, 2009
Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding.
Hein J et al.
Journal of Virology, 2009
Crosstalk between site-specific modifications on p53 and histone H3.
Warnock LJ et al.
Oncogene, 2008
Bub1: escapades in a cellular world.
Williams GL et al.
Cell Cycle (georgetown, Tex.), 2007
Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities.
Li DW et al.
Oncogene, 2006
Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis.
Klampfer L et al.
Oncogene, 2005
Role of phosphorylation in p53 acetylation and PAb421 epitope recognition in baculoviral and mammalian expressed proteins.
Warnock LJ et al.
The Febs Journal, 2005
DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage.
Jack MT et al.
The Journal of Biological Chemistry, 2004
Regulation of p53 stability and function in HCT116 colon cancer cells.
Kaeser MD et al.
The Journal of Biological Chemistry, 2004
Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex.
Goudelock DM et al.
The Journal of Biological Chemistry, 2003
HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype.
Cortés ML et al.
Gene Therapy, 2003
Effect of wild-type, S15D and R175H p53 proteins on DNA end joining in vitro: potential mechanism of DNA double-strand break repair modulation.
Okorokov AL et al.
Carcinogenesis, 2002
Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm2.
Bean LJ et al.
The Journal of Biological Chemistry, 2002
Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV.
Bean LJ et al.
Oncogene, 2001
Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner.
Stewart ZA et al.
Oncogene, 2001
Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity.
Turenne GA et al.
Bmc Cell Biology, 2001
Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding.
Sakaguchi K et al.
The Journal of Biological Chemistry, 2000
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation.
Blattner C et al.
Oncogene, 1999
A role for ATR in the DNA damage-induced phosphorylation of p53.
Tibbetts RS et al.
Genes & Development, 1999
Phosphorylation of p53 serine 15 increases interaction with CBP.
Lambert PF et al.
The Journal of Biological Chemistry, 1998